MBX Biosciences is trading at $49.76, down 5.18%, in a move consistent with broader sector and market pressure; no confirmed company-specific catalyst explains the decline.
- Biotech was down 5.19%, alongside sharp declines in major U.S. indexes.
- Third-quarter results were scheduled for November 5, but the available earnings listing does not confirm they were released.